Company Overview and News

 
Lycopodium named for mineral sands study

2018-05-15 businessnews.com.au
Local engineering firm Lycopodium and Queensland-based Mineral Technologies have been appointed to deliver a pre-feasibility study for Base Resources’ Toliara mineral sands project in Madagascar.

 
Lycopodium appointed for PFS

2018-05-15 businessnews.com.au
Local engineering firm Lycopodium and Queensland-based Mineral Technologies have been appointed to deliver a pre-feasibility study for Base Resources’ Toliara mineral sands project in Madagascar.

 
Base Resources to acquire 85% of Toliara project for $100m

2017-12-20 australianmining.com.au
Base Resources has announced a capital raising of $100 million to acquire an 85 per cent interest in the Madagascan Toliara Sands project from World Titane.

 
Base in $US75m African purchase

2017-12-19 businessnews.com.au
Base Resources has announced that it will purchase a mineral sands project in Madagascar for $US75 million ($100 million) and tap investors for $100 million to fund the acquisition.

 
Oil Search chairman Spence to head rival Santos

2017-10-23 theage.com.au
Oil Search chairman Keith Spence is to head rival energy firm Santos, stepping down from his current role in the Papua New Guinean focused gas company.

 
Oil Search chairman Spence to head rival Santos

2017-10-23 smh.com.au
Oil Search chairman Keith Spence is to head rival energy firm Santos, stepping down from his current role in the Papua New Guinean focused gas company.

 
Keith Spence named as incoming Santos chairman

2017-10-23 perthnow.com.au
EXPERIENCED oil and gas executive Keith Spence has been named as the new chairman of Santos, with the appointment to take effect in February next year.

 
Santos reveals new chairman

2017-10-22 australianmining.com.au
Spence, who has more than 30 years’ experience in the oil and gas industry, has previously held senior positions with Woodside Petroleum and Shell.

 
Base Resources is the ASX Most Active in early afternoon trade

2017-10-09 proactiveinvestors.com.au
Base Resources Ltd (ASX:BSE,AIM:BSE) is the most active stock on the ASX today, with circa 75 million shares changing hands by 12:30pm.

 
Quarterly Activities Report ? June 2017

2017-07-13 londonstockexchange
African mineral sands producer, Base Resources Limited (ASX & AIM: BSE) (“Base Resources” or the “Company”) is pleased to provide a quarterly corporate and operational update for its Kwale Mineral Sands Operations (“Kwale Operations”) in Kenya.  The quarter was characterised by continuing improvement in zircon markets, stabilising ilmenite prices and a positive outlook for rutile.  The continued strong performance of Kwale Operations has reduced net debt by a further US$24.

 
Change of Interest of Significant Shareholder

2017-06-30 londonstockexchange
Base Resources Limited (ASX & AIM: BSE) ("Base Resources") advises that it has today received the following notification.  

 
Change of Interests of Significant Shareholder

2017-06-05 londonstockexchange
Base Resources Limited (ASX & AIM: BSE) ("Base Resources") advises that it has today received the following notification.

 
Change of Interest of Significant Shareholder

2017-06-02 londonstockexchange
Base Resources Limited (ASX & AIM: BSE) ("Base Resources") advises that it has today received the following notification.  

 
Change of Interests of Substantial Shareholder

2017-05-31 londonstockexchange
Base Resources Limited (ASX & AIM: BSE) ("Base Resources") advises that it has today received the following notification.

 
Initial Substantial Shareholder Notice

2017-05-30 londonstockexchange
Base Resources Limited (ASX & AIM: BSE) ("Base Resources") advises that it has today received the following notification.  

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...